Cannabis isn’t the only game in town for playing the stock market
Cannabis stocks have become highly popular with investors, especially over the past 18 months. This trend is going to continue and there are a number of highly valuable cannabis companies worth paying attention to. But, there is another area that is garnering a great deal of support, and which is going to prove to be just as important as cannabis.
Companies that are focusing solely on cannabidiol (CBD), the non-psychoactive compound in cannabis, are ripe. CBD is gaining worldwide acclaim for its healing benefits, made possible without the “high” feeling associated with marijuana. Several companies that are specializing in CBD products are going to lead the stock market revolution.
Some names are easily identifiable. Tilray has been around for a while and recently received approval by the Drug Enforcement Agency (DEA) to import marijuana for medical research. It has also announced the acquisition of Manitoba Harvest, a manufacturer of CBD-infused food and health products, which is going to give the company a distinct advantage in the North American market.
Aurora Cannabis is a name immediately associated with CBD. It seems that a day doesn’t pass where the company isn’t acquiring another company or massaging a new export deal, and Aurora is poised to be one of the strongest companies in the CBD space.
HEXO is at the top, as well. It is involved in a joint venture with Molson Coors Brewing Company, through which CBD-infused beverages will soon hit the market. Given Molson’s global reach, the partnership will see its drinks on shelves around the world in no time.
The last name isn’t one that most people instantly recognize, nor is it one investors might readily consider as a viable alternative. However, BlissCo Cannabis is in a great position to provide huge returns for investors. Its stock is only trading at around $0.25, but it is already up 39% since the beginning of the year. Against its historical averages, the company is undervalued and is poised for a breakout within the next six months.